Table 4.
Risk of HCC development in 394 patients with and without complete virological response at different HCC risk prediction models.
| Variables | Total n=394 |
Persistent viremia n=90 |
Complete virological response n=304 | P-value* |
|---|---|---|---|---|
| CAMD score | 0.018 | |||
| low-risk group, n(%) | 239 (60.7) | 66 (73.3) | 173 (56.9) | |
| intermediate-risk group, n(%) | 124 (31.5) | 20 (22.2) | 104 (34.2) | |
| high-risk group, n(%) | 31 (7.9) | 4 (4.4) | 27 (8.9) | |
| AMAP score | 0.204 | |||
| low-risk group, n(%) | 162 (41.1) | 43 (47.8) | 119 (39.1) | |
| intermediate-risk group, n(%) | 184 (46.7) | 40 (44.4) | 144 (47.4) | |
| high-risk group, n(%) | 48 (12.2) | 7 (7.8) | 41 (13.5) | |
| AASL-HCC score | 0.091 | |||
| low-risk group, n(%) | 177 (44.9) | 48 (53.3) | 129 (42.4) | |
| intermediate-risk group, n(%) | 195 (49.5) | 40 (44.4) | 155 (51.0) | |
| high-risk group, n(%) | 22 (5.6) | 2 (2.2) | 20 (6.6) | |
| HCC-ESCAVT score | 0.424 | |||
| low-risk group, n(%) | 281 (71.3) | 69 (76.7) | 212 (69.7) | |
| intermediate-risk group, n(%) | 100 (25.4) | 19 (21.1) | 81 (26.6) | |
| high-risk group, n(%) | 13 (3.3) | 2 (2.2) | 11 (3.6) | |
| CAMPAS score | 0.538 | |||
| low-risk group, n(%) | 110 (27.9) | 29 (32.2) | 81 (26.6) | |
| intermediate-risk group, n(%) | 151 (38.3) | 31 (34.4) | 120 (39.5) | |
| high-risk group, n(%) | 133 (33.8) | 30 (33.3) | 103 (33.9) | |
| HCC-RESCUE score | 0.111 | |||
| low-risk group, n(%) | 264 (67.0) | 68 (75.6) | 196 (64.5) | |
| intermediate-risk group, n(%) | 104 (26.4) | 19 (21.1) | 85 (28.0) | |
| high-risk group, n(%) | 26 (6.6) | 3 (3.3) | 23 (7.6) | |
| mPAGE-B HCC score | 0.679 | |||
| low-risk group, n(%) | 254 (64.5) | 60 (66.7) | 194 (63.8) | |
| intermediate-risk group, n(%) | 138 (35.0) | 30 (33.3) | 108 (35.5) | |
| high-risk group, n(%) | 2 (0.5) | 0 (0) | 2 (0.7) |
HCC, hepatocellular carcinoma; CAMD, cirrhosis, patient age, male sex, and diabetes; AMAP, age, male, albumin-bilirubin, platelets; AASL, age, albumin, sex, liver cirrhosis; ESC, e antigen seroclearance; AVT, antiviral therapy; HCC-RESCUE, HCC-Risk Estimating Score in CHB patients Under Entecavir; mPAGE-B, modified PAGE-B; CAMPAS, cirrhosis on ultrasonography, age, male gender, platelet count, albumin and liver stiffness. The meaning of the bold values is to highlight statistically significant indicators.
*P value provided in Tables 3 and 4: comparison between patients with and without complete virological response at week 78.